Researchers Develop Wireless Implantable Device to Solve Oxygen Challenge in Cell-Based Drug Delivery
核心洞察
Researchers at Rice University, Carnegie Mellon University, and Northwestern University have developed HOBIT, a wireless implantable device that generates oxygen locally to support high-density cell clusters for drug production.
The device achieved six times higher cell densities than conventional approaches and maintained 65% cell viability after 30 days compared to 20% in control devices without oxygenation.
HOBIT successfully produced three different biologic molecules simultaneously, including antibodies, hormones, and GLP-1 (搜索)-like molecules, demonstrating potential for treating multiple diseases including diabetes (搜索).
Researchers at Rice University and collaborators at Carnegie Mellon University and Northwestern University have successfully developed a breakthrough solution to one of the most persistent challenges in cell-based drug delivery: maintaining sufficient oxygen supply to support high-density cell clusters in implantable devices.
The new system, called the Hybrid Oxygenation Bioelectronics system for Implanted Therapy (HOBIT), addresses the fundamental problem that has limited the clinical viability of implantable cell factories. According to a study published in the journal Device, the device shields a sufficient number of cells from the host immune system in a comfortably small volume while providing access to oxygen and nutrients.
Addressing the Oxygen Bottleneck
"When they are packed into dense clusters, cells compete with each other for oxygen," said Chris Wright, a Rice Ph.D. student who is a first author on the study. "Under the skin, there simply is not enough local supply to support the number of cells you would need for a clinically meaningful dose."
HOBIT is designed to be placed under the skin, an area accessible via minimally-invasive surgery with relatively low risk, but which tends to be poorly oxygenated compared to more vascularized tissues. To overcome this limitation, the device incorporates a miniaturized electrocatalytic oxygenator that uses an iridium oxide-based surface powered by an on-board battery to split water present in surrounding tissue, generating oxygen locally without producing harmful byproducts.
Wireless Integration and Enhanced Performance
Earlier versions of oxygen-generating chips required external wiring, but the current study demonstrates a fully integrated wireless, implantable system that can be remotely adjusted to modulate oxygen production. "We are producing oxygen directly where the cells need it," said Jonathan Rivnay, the Jerome B. Cohen Professor in Engineering at Northwestern University. "That allows us to support much higher cell densities in a much smaller space: Cell densities in HOBIT were roughly six times higher than conventional unoxygenated encapsulation approaches."
The compact device, roughly the size of a folded stick of gum, houses a cell chamber designed to protect cells from the host immune system while allowing nutrients and secreted biologics to flow unimpeded. HOBIT achieves this through a two-stage encapsulation approach: engineered cells are first microencapsulated in alginate hydrogel beads, then loaded into a larger chamber consisting of a semipermeable membrane.
Multi-Drug Production Capability
The encapsulated cells were engineered to continuously produce three biologic molecules representing different therapeutic classes and half-lives: an antibody, a hormone, and exenatide, which is a GLP-1 (搜索)-like molecule. "In addition to solving the oxygenation and cell density problem, the HOBIT platform is also proof of concept that cell factories can be engineered to produce multiple biologic molecules simultaneously," said Omid Veiseh, a professor of bioengineering at Rice and corresponding author on the study.
Promising Preclinical Results
To evaluate performance, the team implanted oxygenated and non-oxygenated control devices in rats for 30 days. Blood measurements showed sustained levels of all three biologics throughout the study period in animals receiving oxygenated implants. In contrast, short-half-life biologics became undetectable by day seven in animals implanted with control devices, while longer-half-life molecules declined steadily over time.
At the end of the testing period, roughly 65% of the cells in the oxygenated devices remained viable compared to roughly 20% in control devices, demonstrating the critical importance of local oxygen generation for maintaining cell function.
Clinical Applications and Future Directions
"The results are very encouraging — HOBIT brings us significantly closer to clinically viable platform," Veiseh said. "If you can compact cells and keep them alive, you open the door to more sophisticated therapies — multiple cell types, regulated secretion, integration with sensing electronics — all within a retrievable device."
The team plans to pursue larger-animal studies and disease-specific applications, including for diabetes (搜索), where transplanted pancreatic islets (搜索) have high yet variable oxygen demands. "Cell therapy offers a different approach, with a single implant that continuously produces the biologic," Veiseh explained. "Our goal is to provide the engineering framework that makes that feasible."
The research represents a significant advancement in the field of implantable drug delivery systems, potentially transforming treatment approaches for numerous diseases by enabling long-term, continuous production of therapeutic biologics directly within the patient's body.